MedImmune v. Genentech: Impact of the Supreme Court Jan. 9 Decision on Patent Licenses

Court Overturns Long-Standing Federal Circuit Position

Recording of a 90-minute CLE webinar with Q&A


Conducted on Wednesday, February 14, 2007

Program Materials

Description

The Supreme Court’s recent ruling in Medimmune Inc. V. Genentech Inc. fundamentally changes the rules of engagement between patent owners and licensees. The decision is certain to impact patent licensing agreements - and trigger significant litigation over agreements.

The Court's decision grants licensees the power to "pay and sue" over the validity of a licensed patent. Some believe the ruling will hinder a patent owner's power over licensees – others fear it will lead to licensors' demands for higher royalty arrangements.

Listen as our authoritative panel reviews the Court’s ruling and examine its short-term and long-range impact for patent owners, licensees, and license agreements.

READ MORE

Benefits

The panel will review these and other key questions:

  • How has Medimmune shifted the balance of power between patent owners and licensees – and how can licensors protect their rights?
  • How will Medimmune impact license negotiations and enforcement?
  • What are the best practices for licensors to protect themselves from patent challenges by licensees?

Faculty

Michael A. O'Shea
Michael A. O'Shea
Partner
Akin Gump Strauss Hauer & Feld

He focuses his practice on patent litigation and licensing. He has litigated numerous patent cases in a wide range of...  |  Read More

Charles Baker
Charles Baker
Partner
Porter & Hedges

He prosecutes and defends complex civil litigation matters, including significant high-profile work on IP matters. He...  |  Read More

David Segal
David Segal
Partner
Gibson Dunn & Crutcher

He is a member of the firm's IP and Technology Practice Groups. He has substantial litigation and transactional...  |  Read More